Medical Information

Anagrelor is a selective thrombopoietin inhibitor primarily used to treat thrombocytosis by reducing platelet count and lowering the risk of thrombosis. The following is a complete explanation of its indications, usage, dosage, and side effects, strictly following the specifications in the drug instructions.

1. Indications

(1) Primary thrombocytosis: reduces platelet count, lowers the risk of thromboembolism and bleeding events, and is listed as an orphan drug indication by the FDA.

(2) Secondary thrombocytosis in bone marrow proliferative diseases: including symptom control of thrombocytosis caused by chronic myeloid leukemia, etc.

2. Usage and dosage

(1) Adult standard dose

The initial dose is 0.5 milligrams four times a day or 1 milligrams twice a day, maintained for at least 7 days. Subsequently adjusted to maintain the minimum effective dose of platelets<600000/microliter, with a weekly increase not exceeding 0.5 milligrams/day.

(2) Child dose

Recommend an initial dose of 0.5 milligrams per day, which can be increased to 0.5 milligrams four times a day. The maintenance dose standard is the same as that for adults, with a maximum dose not exceeding 10 milligrams per day.

(3) Dose limit

The single dose should not exceed 2.5 milligrams. Patients with liver dysfunction should reduce their dosage, and severe liver dysfunction should be avoided.

3. Side effects and treatment

(1) Side effects requiring immediate medical attention

Chest pain, difficulty breathing, arrhythmia, abnormal bleeding, jaundice, etc. may indicate cardiac toxicity or severe blood abnormalities.

(2) Common side effects

Edema, headache, palpitations, nausea, etc., usually mild in severity, may be relieved by continuous medication.

(3) Long term risk

Anemia, interstitial lung disease, pulmonary arterial hypertension, etc. require regular monitoring of blood and cardiopulmonary function.

4. Important precautions

(1) Cardiovascular monitoring: Cardiac function needs to be evaluated before and after treatment, especially for those with a history of underlying heart disease.

(2) Platelet monitoring: Testing every 2 days during the initial stage of treatment and once a week after stabilization to prevent low platelet count.

(3) Pregnancy taboos: Women of childbearing age need contraception unless the benefits outweigh the risks to the fetus.

(4) Drug interactions: Avoid using aspirin in combination as it may increase the risk of bleeding.

5. Drug properties

White opaque capsule with black "063" printed on it, needs to be stored in a dry environment at 15-30 ℃.